{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:01:46Z","timestamp":1785528106951,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"School of Public Health, The Fourth Military Medical University"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72474221"],"award-info":[{"award-number":["72474221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00794-1","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:56:38Z","timestamp":1783994198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unintended consequences of National centralized volume-based drug procurement policy in China: a game theory-based analytical approach for pharmaceutical quality and pricing"],"prefix":"10.1186","volume":"24","author":[{"given":"Siyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"1","key":"794_CR1","first-page":"67","volume":"38","author":"XS Yuan","year":"2018","unstructured":"Yuan XS, Qi Y, Chen CT. Thoughts on Resolving the Inflated Drug Prices through the Supply - side Structural Reform of Medicines. Chin Hosp Manage. 2018;38(1):67\u20138.","journal-title":"Chin Hosp Manage"},{"key":"794_CR2","doi-asserted-by":"crossref","unstructured":"Dayer VW, Grueger J, Sun L, Adamson BJ, Barthold D, Martin K, et al. Evidence and pricing: bridging the comparative effectiveness gap in federal and state drug policy. Value Health. 2026.","DOI":"10.1016\/j.jval.2026.04.014"},{"issue":"1","key":"794_CR3","first-page":"119","volume":"40","author":"LL Yue","year":"2023","unstructured":"Yue LL, Wang B, Liu WF. Research on the High - quality Development of Drug Quantity - based Procurement from the Perspective of the Co - coordinated Reform of Medical Services, Medical Insurance, and Medicine. Chin J Mod Appl Pharm. 2023;40(1):119\u201325.","journal-title":"Chin J Mod Appl Pharm"},{"key":"794_CR4","unstructured":"Notice of the General Office of the State Council on Printing and Distributing the Pilot Plan for the National Organization of Centralized Drug Procurement and Use. The Pilot Plan for the National Organization of Centralized Drug Procurement and Use. The State Council Bulletin, 2019, No. 3. Retrieved from the website of the Chinese Government. https:\/\/www.gov.cn\/gongbao\/content\/2019\/content_5361793.htm"},{"issue":"12","key":"794_CR5","first-page":"53","volume":"42","author":"YJ Yang","year":"2023","unstructured":"Yang YJ, Liu B, Zhang HL, et al. Application and Enlightenment of WHO\u2019s Drug Pricing Method in the Pricing of Chinese Patent Medicines under the Medical Insurance System. Chin Health Econ. 2023;42(12):53\u20136.","journal-title":"Chin Health Econ"},{"issue":"7","key":"794_CR6","first-page":"50","volume":"36","author":"J Xu","year":"2017","unstructured":"Xu J, Xia C, Yang XN. Exploration of the Pricing and Price - adjustment Mechanism Based on the Value of Medicines. Chin Health Econ. 2017;36(7):50\u20133.","journal-title":"Chin Health Econ"},{"key":"794_CR7","unstructured":"Huang SQ, Tian K, Zhang LJ, et al. Research on the impact of quantity - based procurement policy on drug prices in China. Price: Theory Pract. 2019;(5):35\u20138."},{"key":"794_CR8","unstructured":"Li DQ. Promotion of innovation by government procurement: a review of controversial issues. Forum Sci Technol China. 2018;(2):46\u201354."},{"key":"794_CR9","unstructured":"Wang WB, Wang YH, Gan SD. Analysis of the cost composition of winning bidding pharmaceutical enterprises under the background of drug quantity-based procurement. Price: Theory Pract. 2019;(1):56\u20139."},{"issue":"8","key":"794_CR10","first-page":"129","volume":"34","author":"QL Tan","year":"2021","unstructured":"Tan QL, Wang HY. Game Analysis of the Excess Supply Problem between the Joint Procurement Office for the National Organization of Centralized Drug Procurement and Use and the Winning Bidding Enterprises under the Background of Drug Quantity - based Procurement. Med Soc. 2021;34(8):129\u201334.","journal-title":"Med Soc"},{"issue":"7","key":"794_CR11","first-page":"518","volume":"39","author":"XY Wang","year":"2022","unstructured":"Wang XY, Yin WQ, Fan CX, et al. Economic Analysis of the Welfare Effect of the Drug Quantity - based Procurement Policy. Chin Health Service Manage. 2022;39(7):518\u20139.","journal-title":"Chin Health Service Manage"},{"key":"794_CR12","doi-asserted-by":"crossref","unstructured":"Shen M, Liang X. Han Wu. The impact of bioequivalence regulation on pharmaceutical firm outcomes: evidence from China. Soc Sci Med. 2025(380): 118242.","DOI":"10.1016\/j.socscimed.2025.118242"},{"issue":"03","key":"794_CR13","first-page":"119","volume":"36","author":"YW Zhang","year":"2023","unstructured":"Zhang YW, Wang L. A Systematic Review of the Implementation Effect of China\u2019s National Centralized Drug Procurement Policy. Med Soc. 2023;36(03):119\u201324.","journal-title":"Med Soc"},{"key":"794_CR14","doi-asserted-by":"publisher","first-page":"119195","DOI":"10.1016\/j.socscimed.2026.119195","volume":"398","author":"Tao Wang","year":"2026","unstructured":"Tao Wang. Centralized drug procurement and inequality: Therapeutic and geographic spillovers from China\u2019s national volume-based procurement. Soc Sci Med. 2026;398:119195.","journal-title":"Soc Sci Med"},{"issue":"04","key":"794_CR15","first-page":"28","volume":"38","author":"YS Li","year":"2021","unstructured":"Li YS, Kang QF, Han YQ, et al. Research on the Policy Effect of Drug Quantity - based Procurement on Patients\u2019 Medical Burden. Health Econ Res. 2021;38(04):28\u201332.","journal-title":"Health Econ Res"},{"issue":"24","key":"794_CR16","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.3390\/ijerph17249415","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen L, Yang Y, Luo M, et al. The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen. Int J Environ Res Public Health. 2020;17(24):9415.","journal-title":"Int J Environ Res Public Health"},{"issue":"19","key":"794_CR17","first-page":"2410","volume":"32","author":"J Zhao","year":"2021","unstructured":"Zhao J, Li W, Wang GJ. Evaluation of the Implementation Effect of the National Centralized Drug Quantity - based Procurement in a Public Hospital from the Perspective of Value - based Healthcare. China Pharm. 2021;32(19):2410\u20134.","journal-title":"China Pharm"},{"issue":"1","key":"794_CR18","doi-asserted-by":"publisher","first-page":"e014489","DOI":"10.1136\/bmjgh-2023-014489","volume":"9","author":"J Yuan","year":"2024","unstructured":"Yuan J, Li M, Jiang X, Lu ZK. National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond. BMJ Glob Health. 2024;9(1):e014489.","journal-title":"BMJ Glob Health"},{"key":"794_CR19","doi-asserted-by":"publisher","first-page":"1392239","DOI":"10.3389\/fphar.2024.1392239","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Xu JD. China\u2019s national volume-based drug procurement policy promote or hinder pharmaceutical innovation? Front Pharmacol. 2024;15:1392239.","journal-title":"Front Pharmacol"},{"key":"794_CR20","doi-asserted-by":"crossref","unstructured":"Wang Y, Song H, Cao J, Chen Z, Xu F. Low opinion of generic oral anticancer drugs: an unacknowledged factor resulting in medication waste in China. Oncol. 2026;31.","DOI":"10.1093\/oncolo\/oyag057"},{"key":"794_CR21","doi-asserted-by":"crossref","unstructured":"Zhao B, Wu J, Feng XL. Testing the unintended cost effects of health policies for generic substitutions: the case of China\u2019s National Volume-Based Procurement (NVBP) policy. Health Policy Plann. 2025;(40):194\u2013205.","DOI":"10.1093\/heapol\/czae101"},{"issue":"6","key":"794_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/healthcare13060686","volume":"13","author":"D Zhao","year":"2025","unstructured":"Zhao D, Zhou Z. Intended and Unintended Impacts of \u20184\u2009+\u20097\u2019 Volume-Based Drug Procurement on the Use of Drugs in China: A Natural Experimental Study. Healthcare. 2025;13(6):686.","journal-title":"Healthcare"},{"issue":"11","key":"794_CR23","first-page":"1715","volume":"52","author":"XL Wu","year":"2024","unstructured":"Wu XL, Cui XY. Mediating Effect of Medication Beliefs between Illness Perception and Secondary Prevention Medication Adherence in Patients with Ischemic Cardiovascular Disease. Mod Med. 2024;52(11):1715\u201320.","journal-title":"Mod Med"},{"issue":"2","key":"794_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pharp.2025.06.003","volume":"1","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Zhang J, Gong C. Li Yang.Impacts of China\u2019s National Volume-Based Procurement policy on the pharmaceutical industry: A systematic review. Pharmacoeconomics Policy. 2025;1(2):63\u201372.","journal-title":"Pharmacoeconomics Policy"},{"issue":"09","key":"794_CR25","first-page":"24","volume":"40","author":"JP Xie","year":"2021","unstructured":"Xie JP, Hu ZX, Wang YR, et al. Analysis of the Impact of the National Centralized Drug Procurement Policy on Drug Prices, Expenses, and Generic Drug Substitution in the Four Municipalities Directly under the Central Government. Chin Health Econ. 2021;40(09):24\u20138.","journal-title":"Chin Health Econ"},{"key":"794_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12962-025-00664-2","volume":"23","author":"R Yan","year":"2025","unstructured":"Yan R, Miao Z, Cao F. Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study. Cost Eff Resour Alloc. 2025;23:62.","journal-title":"Cost Eff Resour Alloc"},{"key":"794_CR27","unstructured":"Wang JC, Xu Q, Ding X, Li Z, He C, Liu B, Wei Z. ProcureGym: a multi-agent markov game framework for modeling national volume-based drug procurement."},{"key":"794_CR28","volume-title":"Welfare Effect of Network Compatibility Promotion Under Strategic R&D Competition: The Role of Consumer Expectations in a Hotelling Model","author":"T Toshimitsu","year":"2026","unstructured":"Toshimitsu T. Welfare Effect of Network Compatibility Promotion Under Strategic R&D Competition: The Role of Consumer Expectations in a Hotelling Model. Nishinomiya, Japan: School of Economics, Kwansei Gakuin University; 2026."},{"key":"794_CR29","doi-asserted-by":"publisher","first-page":"112710","DOI":"10.1016\/j.econlet.2025.112710","volume":"257","author":"P David","year":"2025","unstructured":"David P. Myatt, David Ronayne,Bertrand competition and captive customers. Econ Lett. 2025;257:112710.","journal-title":"Econ Lett"},{"issue":"08","key":"794_CR30","first-page":"13","volume":"36","author":"ZX Tan","year":"2019","unstructured":"Tan ZX, Fan S. Challenges and Countermeasures for Pharmaceutical Enterprises under the Background of the 4\u2009+\u20097 Quantity - based Centralized Drug Procurement. Health Econ Res. 2019;36(08):13\u20135.","journal-title":"Health Econ Res"},{"key":"794_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/jems.12632","volume":"34","author":"V Wattal","year":"2025","unstructured":"Wattal V. Competitive Entry in the Market for Branded Generic Drugs. J Econ Manag Strategy. 2025;34:1018\u201337.","journal-title":"J Econ Manag Strategy"},{"key":"794_CR32","unstructured":"Li SX, Shen TZ. Research on the implementation effect of China\u2019s drug quantity - based procurement policy: also analyzing the impact on the performance and innovation ability of pharmaceutical enterprises. Price: Theory Pract. 2020;(11):49\u201352."},{"issue":"02","key":"794_CR33","first-page":"36","volume":"14","author":"YH Wan","year":"2021","unstructured":"Wan YH, Xu W, Lu NN, et al. Analysis of the Implementation Effect of the 4\u2009+\u20097 Centralized Quantity - based Procurement: Based on the Drug Sales Data in 9 Pilot Areas. Chin J Health Policy. 2021;14(02):36\u201343.","journal-title":"Chin J Health Policy"},{"issue":"02","key":"794_CR34","first-page":"50","volume":"43","author":"W Deng","year":"2024","unstructured":"Deng W, Wu YX. Impact of the Centralized Procurement Policy on the R & D Efficiency of Pharmaceutical Enterprises: An Empirical Test from A - share Listed Companies in China. J Industrial Technological Econ. 2024;43(02):50\u20139.","journal-title":"J Industrial Technological Econ"},{"key":"794_CR35","unstructured":"National Healthcare Security Administration. Notice on Disqualifying Guangzhou Hehe Pharmaceutical Co., Ltd.\u2019s Methocarbamol Injection from the National VBP Winning-Bid Status and Placing the Company and Its Contract Manufacturer, Chengdu Tiantaishan Pharmaceutical Co., Ltd., on the List of Violators. 2026-04-03. https:\/\/www.nhsa.gov.cn\/art\/2026\/4\/3\/art_187_20113.html"},{"key":"794_CR36","unstructured":"Xi\u2019an Daily. Shaanxi Province Launches Price Governance for 83 Types of Traditional Chinese Medicine Patent Medicines. 2025-08-26. https:\/\/epaper.xiancn.com\/xdbjb\/pc\/html\/202508\/26\/content_293264.html."}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00794-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:19Z","timestamp":1785521839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00794-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00794-1","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Disclaimers","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}